Welcome to the IDT family!

Your product is now available from Integrated DNA Technologies.

Many of the Swift products you have grown to love are now part of our new complete portfolio, xGen™ NGS. Through this new partnership we are pleased to offer you comprehensive next generation sequencing solutions.

xGen NGS—made for you.

Unsure of what products are available? Or, perhaps you’d like guidance on which products are compatible? If so, try our xGen NGS Solutions Builder Tool today.

Welcome to the IDT family!

Find Archer now at IDT!

All Archer information is now available on IDT’s website. You can view Archer assays alongside IDT’s xGen™ NGS portfolio to find the best next generation sequencing solution for your lab.

Confidently detect more with Archer NGS assay solutions for your solid tumor, blood cancer, immune profiling, and genetic disease research.

Explore how our NEW cGMP gRNA manufacturing service can accelerate your CRISPR therapeutics project

More posts in DECODED

  • The importance of HRD genomic signature assessment
  • Customizing CAR-T cells using the CRISPR-Cas9 system
  • Tackling sickle cell disease with precise and efficient gene editing
  • Analyze your CRISPR genome edits with IDT's cloud-based software
  • When and how to use nickases for efficient genome editing
  • Protocol tips to boost your NGS target capture success
  • ve-SEQ: An improved approach to high throughput, whole genome viral sequencing
  • How to clone with IDT Gene Fragments
  • How to improve SNV and indel detection in an exome NGS assay
  • Tips for designing spike-in controls for next generation sequencing analysis
  • Target enrichment identifies mutations that confer fitness effects
  • Targeted sequencing: Hybridization capture or amplicon sequencing?
  • CRISPR knock-out: Tips and tricks
  • Successful CRISPR genome editing in hard-to-transfect cells (i.e., Jurkat cells)
  • How to resuspend, store, and improve the longevity of your IDT Gene Fragments
  • An ASO modification that enhances nuclease resistance, lowers toxicity, and increases binding affinity
  • Navigating the regulatory landscape: A business perspective on cell and gene therapy approvals
  • xGen™ Adaptase™ and Normalase™ technology: 6 key facts to understand
  • Calculations: Converting from nanograms to copy number
  • What is CRISPR screening?
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9